LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by date 45 pages found matching Zetia- New Vytorin Study Results on the Way
Sep-27-14 Washington, DC Another study is set to be released regarding the effectiveness of Vytorin , a drug that combines ezetimibe (known by the brand name Zetia) and simvastatin (known by the brand name Zocor). Whether the study will confirm previous findings that question the effectiveness of combining Zetia and Zocor is not known. Some previous studies have... - Zetia Raises Heart Attack Risks
Feb-2-08 Whitehouse Station, NJ: The Food and Drug Administration (FDA) said, on Friday (Jan 25, 2008), that they will review the safety and efficacy of Zetia /Zocor (Vytorin) after results from the ENHANCE trial suggested that the combination had no significant reduction in atherosclerotic-plaque progression. Steven Nissen, M.D., director of cardiovascular med... - Zetia: Patient Complains About Severe Muscle Pain
Jan-7-08 Doraville, GA: Charles S. says he is annoyed by Zetia. The problem is that within days of taking the drug, he experienced extreme muscle pain—pain that required steroids for relief. Charles has no doubt that the cause of his muscle pain was Zetia. "I was requested to take Zetia for cholesterol control, of course," Charles says. "So I did start t... - $688M Settlements Reached in Vytorin and Zetia ENHANCE Securities Class Actions
New York, NY: Settlements totalling $688 million have been reached in the securities class actions pending against Merck & Co. Inc. ("Merck"), Schering-Plough Corporation ("Schering"), Merck/Schering-Plough Pharmaceuticals, certain of the Companies' directors and officers, and the underwriters of a 2007 Schering stock offering. The settlements, rea... - Vytorin and Zetia Setback
Nov-15-09 Washington, DC How well do Vytorin and Zetia work? According to a new study released today, possibly not at all. Doctors are now questioning whether these two blockbuster cholesterol drugs should even be prescribed. This new study found that ezetimibe, the active ingredient in both Vytorin and Zetia, is significantly less effective at reducin... - Ezetrol: America's Problems are Canada's Problems... and You're Paying for Them
Feb-28-08 Ottawa, ON Nowadays, Canada's neighbors include the likes of pharmaceutical giants Merck/Schering Plough ; they also include the US federal Food and Drug Administration (FDA). Merck/Schering and its Canadian subsidiary Merck Frosst is the big pharma consortium that manufactures and sells Ezetrol (Zetia in the US market), the anti-cholesterol drug that i... - Schering-Plough: Dragging Heels on Vytorin Study, a Breach of ERISA?
Feb-5-08 Kenilworth, NJ The long-awaited, and long-delayed release of the ENHANCE study on the effects and efficacy of the cholesterol drug Vytorin (Zocor combined with Zetia) may have done more than raise the ire of doctors and the medical community: it also may have ticked off investors of Schering-Plough , one of the two manufacturers involved in Vytorin. The... - ENHANCE Test Results Show Zetia Does Not Reduce Artery Plaque
Jan-17-08 Dallas, TX: After a two-year delay, Merck/Schering-Plough Pharmaceuticals has released the ENHANCE test results for its controversial Vytorin combination drug. Vytorin combines Merck/Schering's Zetia and the statin drug Zocor (generic simvastatin). The tests showed that Vytorin performs no better than simvastatin alone in reducing plaque buildup in the a... - Zetia/Vytorin: What Did They Know and When Did They Know It?
Feb-3-08 Kenilworth, NJ: The scandal over Merck/Schering-Plough's long delay in releasing the results of the ENHANCE tests of its big-bucks anti-cholesterol medication Vytorin continues to grow—to the extent that The Wall Street Journal now calls it "Vytoringate". And like its predecessor scandal, the focus of investigations has come down to a simple question: Wh... - Critics Question Liptruzet
May-5-13 Washington, DC Even though Liptruzet has only just been introduced on the market, at least one critic is questioning why the drug received approval. Liptruzet is a combination of Lipitor and Zetia, but Steven Nissen, of the Cleveland Clinic, says that because Zetia has not been proven to prevent heart attacks and strokes, approving it in combination with a... - Zetia/Vytorin: Whose Word Can You Trust?
Feb-11-08 Washington, DC The long-delayed release of the ENHANCE testing results for Merck/Schering-Plough's Vytorin anti-cholesterol drug on January 14 brought on a storm of responses. The ENHANCE results indicated that Vytorin, which combines Merck/Schering's Zetia with generic simvastatin (Zocor), did lower patients' LDL (bad) cholesterol somewhat better than s... - Merck, Schering Settle Vytorin Zetia Class Action
Merck and Schering Plough have entered into $41.5 million settlement of class action lawsuits related to claims against their shared cholesterol medication Vytorin and Zetia. The suit revolved around allegations that the results from the Enhance Trial raised questions about the efficacy of the Zetia and Vytorin. The settlement will resolve approxi... - Demanda Colectiva por la Comercializacion Fraudulenta de Vytorin
Los fabricantes de la droga de colesterol Vytorin están bajo fuego por supuestamente hacer falsas reclamaciones en su campaña de marketing. El General Fiscal de Nueva York, Andrew Cuomo está investigando si la campaña de marketing de Vytorin viola de las leyes estatales relativas a la publicidad falsa. Specifically, offici... - Possible Merck ERISA Violation Regarding Vytorin
Apr-29-08 Whitehouse Station, NJ When Merck dragged its feet for 21 months before releasing the ENHANCE study shaming Vytorin , the manufacturer allegedly did more than delay the bad news: it may have also delayed the returns, and derailed the retirement plans of thousands of investors unaware of a ticking time bomb. But Merck knew, and in so doing may have breac... - Congressional Investigation and Class Action Lawsuit Target Zetia Manufacturers
Jan-23-08 Washington, DC: The House committee that has been investigating Merck/Schering-Plough's two-year delay in releasing the ENHANCE test results for its Vytorin combination drug now wants information on the company's marketing practices. The results of the ENHANCE tests, which were completed in April 2006, were only released in January 2008. The results sho... - Vytorin Brightens with IMPROVE-IT, but Vytorin Lawsuits Remain
Mar-27-15 San Diego, CA The folks at Merck & Co. and their Vytorin partner Schering-Plough Corp. can be forgiven if they are enjoying the re-birth of Vytorin and the accompanying optimism after enduring the scorn that accompanied the delayed release of the ENHANCE study in 2008. The most recent “IMPROVE-IT” study was designed to foster a better outc... - Zetia and Vytorin: Never Say Never
Jan-29-15 Washington, DC If there is one thing to be said about pharmaceutical companies, it remains that they never, ever give up. Not until a product is deemed so unsafe that it is physically pulled from the market, will a manufacturer finally wave the white flag. This is especially true in the statin sector, which is the biggest piece of the pie with potential to... - Study Finds Benefit to Vytorin, but Is It Credible?
Nov-20-14 Chicago, IL A study released today suggests that Vytorin , a drug that combines Zetia and Zocor, is more effective than Zetia alone at preventing heart attack and other heart-related health problems. The study is good news for Merck, who has been under fire for its handling of Vytorin. But other previous studies gave conflicting results regarding Vytori... - Medical Industry Waits for Study on Vytorin
Oct-29-14 Washington, DC Less than a month away is the expected deadline for the medical world to hear the results of a study on Vytorin . The study has been undertaken to add to the published literature about Vytorin side effects and Vytorin effectiveness. So far, at least two studies regarding the drug, which combines ezetimibe (Zetia) and simvastatin (Zocor),... - Niacin Found to Be More Effective than Vytorin at Lowering Cholesterol
Nov-26-09 Orlando, FL According to a recent study from the New England Journal of Medicine, generic B vitamin Niacin was found to be more effective at reducing levels of arterial plaque than Vytorin or Zetia. The limited study of 208 patients found that those who used ezetimibe, the active ingredient in Vytorin and Zetia, experienced greater risk of health atta...